Rockville , Aug. 03, 2023 (GLOBE NEWSWIRE) -- According to a new industry analysis by Fact.MR, a market research and competitive intelligence provider, the global seropositive rheumatoid arthritis treatment market is valued at US$ 32.30 billion in 2023 and is forecasted to increase at a CAGR of 5.3% from 2023 to 2033.
Seropositive rheumatoid arthritis (RA) is an autoimmune disorder characterized by chronic inflammation of the joints, leading to pain, stiffness, and swelling. It is called seropositive because of the presence of specific autoantibodies in the patient’s blood, including rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. The condition affects millions of people worldwide and significantly impacts their quality of life. Over the years, advancements in medical science have led to the development of various treatment options contributing to the growth of the seropositive rheumatoid arthritis treatment market.
Get Free Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=8800
Biological drugs and disease-modifying anti-rheumatic drugs (DMARDs) are emerging as the effective treatment option for seropositive RA. These drugs target specific immune pathways and show promising results in managing disease progression and improving patients’ symptoms. Also, the combination of therapies plays a vital role in the treatment of seropositive rheumatoid arthritis.
With the growing understanding of the heterogeneity of RA, there is a shift toward personalized medicines. Biomarker testing is gaining importance in identifying patients who are more likely to respond to specific treatments, enabling physicians to choose the most effective therapy for each individual. As the patents for some biological drugs are expiring, demand for biosimilars is expected to expand, generating opportunities for both existing as well as new players. Biosimilars offer a more cost-effective alternative to their originator biologics, improving patient access to advanced treatments.
Report Attributes | Details |
| Forecast Period | 2023 - 2033 |
| Value Projection (2033) | US$ 54.30 Billion |
| Growth Rate (2023-2033) | 5.3% CAGR |
| No. of Pages | 170 pages |
| No. of Tables | 84 Tables |
| No. of Figures | 112 Figures |
Key Takeaways from Market Study
- The global seropositive rheumatoid arthritis treatment market is projected to reach US$ 54.3 billion by 2033.
- High incidence of seropositive rheumatoid arthritis and better access to advanced treatments are driving the growth of the United States market for seropositive rheumatoid arthritis treatment.
- Sales of seropositive rheumatoid arthritis drugs in Germany are forecasted to rise at a CAGR of 5.4% from 2023 to 2033.
- The market in China is forecasted to expand at a CAGR of 8.5% through 2033.
- Demand for disease-modifying anti-rheumatic drugs (DMARDs) is estimated to rise at a CAGR of 5.6% over the next 10 years.
“Rising prevalence of seropositive RA, especially among the aging population, is stimulating the demand for drugs used in the treatment of seropositive rheumatoid arthritis,” says Fact.MR analyst.
Competitive Analysis
Ley market players such as:-
AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Pfizer Inc., Alkem Laboratories, and Roche Holding AG are investing heavily in clinical trials, product launches, and marketing to gain a competitive edge.
- Teva and Celltrion Healthcare introduced the rheumatoid arthritis medication TRUXIMA (rituximab-abbs) injectable in May 2020.
- Alkem Laboratories introduced ibuprofen and famotidine pills in August 2021 to treat osteoarthritis and rheumatoid arthritis patients in the United States.
Seropositive Rheumatoid Arthritis Treatment Industry Research Segmentation
- By Drug Class:
- Corticosteroids
- Non-steroidal Anti-inflammatory Drugs (NSAIDs)
- Steroids
- Disease-modifying Anti-rheumatic Drugs (DMARDs)
- Biologics
- By Route of Administration:
- Oral
- Subcutaneous
- Intravenous
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- e-Commerce
- By Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia & Oceania
- MEA
Get Customization on this Report for Specific Research Solutions:
https://www.factmr.com/connectus/sample?flag=RC&rep_id=8800
More Valuable Insights on Offer
Fact.MR, in its new offering, presents an unbiased analysis of the global seropositive rheumatoid arthritis treatment market, presenting historical demand data (2018 to 2022) and forecast statistics for the period (2023 to 2033).
The study divulges essential insights into the market based on drug class (corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), steroids, disease-modifying anti-rheumatic drugs (DMARDs), biologics), route of administration (oral, subcutaneous, intravenous), and distribution channel (hospital pharmacies, retail pharmacies, e-Commerce), across five major regions of the world (North America, Europe, Asia Pacific, Latin America, and MEA).
Explore More Trending Studies Published by Fact.MR Research:
Rheumatoid Arthritis Stem Cell Therapy Market: The global rheumatoid arthritis stem cell therapy market is anticipated to surpass the valuation of USD 33.30 Billion by end of the forecast period i.e. 2032.
Arthritis Therapeutics Market: The arthritis therapeutics market is estimated to grow 1.5x during the forecast period (2020 - 2027).
Sterile Compounding Pharmacies Market: Sales of injections are expected to top US$ 5.3 Billion by the end of 2031
About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client’s satisfaction.
Contact:
US Sales Office
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583, +353-1-4434-232 (D)
Sales Team: sales@factmr.com
Follow Us: LinkedIn | Twitter | YouTube
